Dr. Miller is a practicing hospitalist, health policy researcher, and health policy analyst. He serves as an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine and an Assistant Professor (courtesy) at the Johns Hopkins Carey Business School. His research focuses on payment policy, FDA regulatory pathways, and healthcare competition policy.
Dr. Miller previously served as a Medical Officer in the Office of New Drugs at the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration, where he focused on pre- and post-market safety regulation, including the review and approval of valbenazine, a first-in-class breakthrough new molecular entity. He also served as a Senior Policy Fellow for Health IT at the Federal Communications Commission, in addition to serving as a Special Advisor in the Federal Trade Commission's Office of Policy Planning. At the FTC, he worked on competition policy and served as an in-house physician expert for the Bureau of Competition, assisting in merger review and enforcement in health systems, pharmaceuticals, and retail drug stores, including the FTC's successful action blocking the $7 billion Advocate - NorthShore merger. Prior to the FTC, Dr. Miller was a Fellow at the Centers for Medicare & Medicaid Innovation, where he co-managed the ACO Investment Model, a $114 million project focused on ACOs in rural areas.
He is currently a member of the Medicare Evidence Development & Coverage Advisory Committee and a consultant to government agencies.